These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 20962589

  • 1. p53-dependent repression of polo-like kinase-1 (PLK1).
    McKenzie L, King S, Marcar L, Nicol S, Dias SS, Schumm K, Robertson P, Bourdon JC, Perkins N, Fuller-Pace F, Meek DW.
    Cell Cycle; 2010 Oct 15; 9(20):4200-12. PubMed ID: 20962589
    [Abstract] [Full Text] [Related]

  • 2. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.
    Fischer M, Quaas M, Nickel A, Engeland K.
    Oncotarget; 2015 Dec 08; 6(39):41402-17. PubMed ID: 26595675
    [Abstract] [Full Text] [Related]

  • 3. Association of p21 with NF-YA suppresses the expression of Polo-like kinase 1 and prevents mitotic death in response to DNA damage.
    Lin YC, Chen YN, Lin KF, Wang FF, Chou TY, Chen MY.
    Cell Death Dis; 2014 Jan 09; 5(1):e987. PubMed ID: 24407240
    [Abstract] [Full Text] [Related]

  • 4. Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1).
    Kreis NN, Sommer K, Sanhaji M, Krämer A, Matthess Y, Kaufmann M, Strebhardt K, Yuan J.
    Cell Cycle; 2009 Feb 01; 8(3):460-72. PubMed ID: 19177004
    [Abstract] [Full Text] [Related]

  • 5. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
    Lin YC, Sun SH, Wang FF.
    Cell Signal; 2011 Nov 01; 23(11):1816-23. PubMed ID: 21726628
    [Abstract] [Full Text] [Related]

  • 6. Nitric oxide down-regulates polo-like kinase 1 through a proximal promoter cell cycle gene homology region.
    Zhang J, Wang S, Kern S, Cui X, Danner RL.
    J Biol Chem; 2007 Jan 12; 282(2):1003-9. PubMed ID: 17121839
    [Abstract] [Full Text] [Related]

  • 7. p53 Suppresses E2F1-dependent PLK1 expression upon DNA damage by forming p53-E2F1-DNA complex.
    Zhou Z, Cao JX, Li SY, An GS, Ni JH, Jia HT.
    Exp Cell Res; 2013 Dec 10; 319(20):3104-15. PubMed ID: 24076372
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Molecular interactions of polo-like kinase 1 in human cancers.
    Weng Ng WT, Shin JS, Roberts TL, Wang B, Lee CS.
    J Clin Pathol; 2016 Jul 10; 69(7):557-62. PubMed ID: 26941182
    [Abstract] [Full Text] [Related]

  • 12.  p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
    Sanhaji M, Kreis NN, Zimmer B, Berg T, Louwen F, Yuan J.
    Cell Cycle; 2012 Feb 01; 11(3):543-53. PubMed ID: 22262171
    [Abstract] [Full Text] [Related]

  • 13. Escape from p21-mediated oncogene-induced senescence leads to cell dedifferentiation and dependence on anti-apoptotic Bcl-xL and MCL1 proteins.
    de Carné Trécesson S, Guillemin Y, Bélanger A, Bernard AC, Preisser L, Ravon E, Gamelin E, Juin P, Barré B, Coqueret O.
    J Biol Chem; 2011 Apr 15; 286(15):12825-38. PubMed ID: 21292770
    [Abstract] [Full Text] [Related]

  • 14. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
    Van den Bossche J, Deben C, De Pauw I, Lambrechts H, Hermans C, Deschoolmeester V, Jacobs J, Specenier P, Pauwels P, Vermorken JB, Peeters M, Lardon F, Wouters A.
    Mol Oncol; 2019 May 15; 13(5):1196-1213. PubMed ID: 30859681
    [Abstract] [Full Text] [Related]

  • 15. Centrosomal protein 55 (Cep55) stability is negatively regulated by p53 protein through Polo-like kinase 1 (Plk1).
    Chang YC, Wu CH, Yen TC, Ouyang P.
    J Biol Chem; 2012 Feb 03; 287(6):4376-85. PubMed ID: 22184120
    [Abstract] [Full Text] [Related]

  • 16. SAK, a new polo-like kinase, is transcriptionally repressed by p53 and induces apoptosis upon RNAi silencing.
    Li J, Tan M, Li L, Pamarthy D, Lawrence TS, Sun Y.
    Neoplasia; 2005 Apr 03; 7(4):312-23. PubMed ID: 15967108
    [Abstract] [Full Text] [Related]

  • 17. The RNA helicase/transcriptional co-regulator, p68 (DDX5), stimulates expression of oncogenic protein kinase, Polo-like kinase-1 (PLK1), and is associated with elevated PLK1 levels in human breast cancers.
    Iyer RS, Nicol SM, Quinlan PR, Thompson AM, Meek DW, Fuller-Pace FV.
    Cell Cycle; 2014 Apr 03; 13(9):1413-23. PubMed ID: 24626184
    [Abstract] [Full Text] [Related]

  • 18. Polo-like kinase 1: target and regulator of transcriptional control.
    Martin BT, Strebhardt K.
    Cell Cycle; 2006 Dec 03; 5(24):2881-5. PubMed ID: 17172872
    [Abstract] [Full Text] [Related]

  • 19. Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation.
    Koida N, Ozaki T, Yamamoto H, Ono S, Koda T, Ando K, Okoshi R, Kamijo T, Omura K, Nakagawara A.
    J Biol Chem; 2008 Mar 28; 283(13):8555-63. PubMed ID: 18174154
    [Abstract] [Full Text] [Related]

  • 20. Polo-like kinase 1 inhibits DNA damage response during mitosis.
    Benada J, Burdová K, Lidak T, von Morgen P, Macurek L.
    Cell Cycle; 2015 Mar 28; 14(2):219-31. PubMed ID: 25607646
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.